Adverse Drug Event Prevention

Abstract

Adverse drug events (ADEs) have been highlighted as a national patient safety and public health challenge by the National Action Plan for Adverse Drug Event Prevention (ADE Action Plan), which was released by the Office of Disease Prevention and Health Promotion in August 2014. The following October, the ADE Prevention: 2014 Action Plan Conference provided an opportunity for federal agencies, national experts, and stakeholders to coordinate and collaborate in the initiative to reduce preventable ADEs. The single-day conference included morning plenary sessions focused on the surveillance, evidence-based prevention, incentives and oversights, and additional research needs of the drug classes highlighted in the ADE Action Plan: anticoagulants, diabetes agents, and opioids. Afternoon breakout sessions allowed for facilitated discussions on measures for tracking national progress in ADE prevention and the identification of opportunities to ensure safe and high-quality health care and medication use.

Effect of telemedicine intervention on hypoglycaemia in diabetes patients: A systematic review and meta-analysis of randomised controlled trials

“…1 With the development of science and technology, there has been increasing acceptance of the importance of individualizing glycemic management and assessment of risk for adverse events, especially hypoglycaemia. 2,3 Because of therapeutic efforts to maintain target hemoglobin A1c (HbA1c), an increasing number of Diabetes Mellitus (DM) patients currently live with the risk of hypoglycaemia. [4][5][6] The American Diabetes Society Working Group defines hypoglycaemia as 3.9 mmol/L whether the patient fasting or not, and divides it into five categories: 7,8 1.…”

“…1 With the development of science and technology, there has been increasing acceptance of the importance of individualizing glycemic management and assessment of risk for adverse events, especially hypoglycaemia. 2,3 Because of therapeutic efforts to maintain target hemoglobin A1c (HbA1c), an increasing number of Diabetes Mellitus (DM) patients currently live with the risk of hypoglycaemia. 4–6 The American Diabetes Society Working Group defines hypoglycaemia as 3.9 mmol/L whether the patient fasting or not, and divides it into five categories: 7,8 Severe hypoglycaemia, which needs sugar, carbohydrates, or other related rescue measures provided by others. Symptomatic hypoglycaemia, which shows symptoms and a plasma glucose < 3.9 mmol/L. Asymptomatic hypoglycaemia, which presents with no symptoms, but has a plasma glucose < 3.9 mmol/L. Suspected symptoms, which present with related symptoms of hypoglycaemia and a blood glucose level that could not be monitored during the attack, but which symptoms were relieved after eating. Relative hypoglycaemia, which presents typical hypoglycemic symptoms but actual measured blood glucose levels > 3.9 mmol/L, which is common in those diabetic patients who live long-term with poorly controlled glycemic levels. …”

Development of the Leapfrog Group’s Bar Code Medication Administration Standard to Address Hospital Inpatient Medication Safety

“…Medication errors are the most common type of error in hospitals and reflect a leading cause of avoidable harm to patients 1 . Many medication errors result in serious adverse drug events (ADEs), of which approximately 20% are life-threatening 2–4 . The Institute of Medicine estimated that medication errors cause 1 in 131 outpatient deaths and 1 in 854 inpatient deaths 5 .…”

Evaluation of preventable adverse drug reactions by implementation of the nationwide network of prospective drug utilization review program in Korea

“…An adverse drug event (ADE) is defined as “an injury resulting from medical intervention related to a drug” [ 1 ]. The term encompasses harms that occur in any health care setting that are directly due to the drug including but not limited to medication errors, adverse drug reactions (ADRs), allergic reactions, and overdoses [ 2 ].…”